IDH1 and glioma: The results of several other studies are highly anticipated, including those of the ongoing trial of an IDH1-R132H dendritic cell vaccine in patients with IMG (NCT02771301), the recently completed RESIST trial which investigated the use of PEPIDH1M for patients with recurrent grade 2 gliomas (NCT02193347), and the newly opened ViCToRy trial combining PEPIDH1M with the dual IDH1/2 inhibitor vorasidenib (NCT05609994).